Cortese, Rosa
Battaglini, Marco
Stromillo, Maria Laura
Luchetti, Ludovico
Leoncini, Matteo
Gentile, Giordano
Gasparini, Daniele
Plantone, Domenico
Altieri, Manuela
D’Ambrosio, Alessandro
Gallo, Antonio
Giannì, Costanza
Piervincenzi, Claudia
Pantano, Patrizia
Pagani, Elisabetta
Valsasina, Paola
Preziosa, Paolo
Tedone, Nicolo’
Rocca, Maria Assunta
Filippi, Massimo
De Stefano, Nicola
,
Bisecco, Alvino
Esposito, Fabrizio
De Rosa, Alessandro
Ruggieri, Serena
Tommasin, Silvia
Petsas, Nikolaos
Storelli, Loredana
Sala, Stefania
Funding for this research was provided by:
Università degli Studi di Siena
Article History
Received: 26 October 2023
Revised: 28 February 2024
Accepted: 29 February 2024
First Online: 14 May 2024
Declarations
:
: Ethics approval was received from the local Institutional Review Board at each Research Center (Milan, Naples, Rome, Siena), and written informed consent was obtained from all subjects. The study had been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: R. Cortese was awarded a MAGNIMS-ECTRIMS fellowship in 2019; she received speaker honoraria from Roche, Merck Serono and Sanofi and travel support for conferences by Novartis. A. Gallo received speaker and consulting fees from Biogen, Genzyme, Merck Serono, Mylan, Novartis, Roche, and Teva, and receives research sup- port from Fondazione Italiana Sclerosi Multipla. E. Pagani received honorarium from Biogen. P. Valsasina received honorarium from Biogen. P. Preziosa received research support from Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla; honoraria from Roche, Biogen, Novartis, Merck Serono, Bristol Myers Squibb, and Genzyme. M.A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; and speaker honoraria from AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. She receives research support from the MS Society of Canada, the Italian Ministry of Health, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders. M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Associate Editor of Radiology, and Associate Editor of Neurological Sciences; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). N. De Stefano has received honoraria from Biogen-Idec, Bristol Myers Squibb, Celgene, Genzyme, Immunic, Merck Serono, Novartis, Roche and Teva for consulting services, speaking, and travel support. He serves on advisory boards for Merck, Novartis, Biogen-Idec, Roche, and Genzyme, Immunic and he has received research grant support from the Italian MS Society. M. Battaglini, M.L. Stromillo, L. Luchetti, M. Leoncini, G. Gentile, D. Gasparini, D. Plantone, M. Altieri, A. d’Ambrosio, C. Gianni’, C. Piervincenzi, N. Tedone have nothing to disclose.